139 related articles for article (PubMed ID: 30710095)
1. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
2. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
[TBL] [Abstract][Full Text] [Related]
3. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
4. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
5. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
[TBL] [Abstract][Full Text] [Related]
6. Most colitis associated carcinomas lack expression of LGR5: a preliminary study with implications for unique pathways of carcinogenesis compared to sporadic colorectal carcinoma.
Iwaya M; Ota H; Nakajima T; Uehara T; Riddell R; Conner J
BMC Cancer; 2021 Feb; 21(1):119. PubMed ID: 33541282
[TBL] [Abstract][Full Text] [Related]
7. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
[TBL] [Abstract][Full Text] [Related]
8. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
9. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
10. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB; Schaeffer DF
Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
[TBL] [Abstract][Full Text] [Related]
11. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
[TBL] [Abstract][Full Text] [Related]
12. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
13. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
[TBL] [Abstract][Full Text] [Related]
14. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
15. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
16. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
17. A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.
Le Page C; Köbel M; Meunier L; Provencher DM; Mes-Masson AM; Rahimi K
J Pathol Clin Res; 2019 Jul; 5(3):177-188. PubMed ID: 30924313
[TBL] [Abstract][Full Text] [Related]
18. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
19. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.
Walsh MD; Clendenning M; Williamson E; Pearson SA; Walters RJ; Nagler B; Packenas D; Win AK; Hopper JL; Jenkins MA; Haydon AM; Rosty C; English DR; Giles GG; McGuckin MA; Young JP; Buchanan DD
Mod Pathol; 2013 Dec; 26(12):1642-56. PubMed ID: 23807779
[TBL] [Abstract][Full Text] [Related]
20. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]